Category: Silo Wellness

For media inquiries:

Catherine Snider

Kaiser & Partners

Marley One Launches The First Global Functional And Psychedelic Mushroom Brand

Bob Marley’s family want to sell you some mushrooms.

The Marley family has partnered up with Silo Wellness, a leading global psychedelics company, to launch Marley One, the first global functional and psychedelic mushroom consumer brand.

The initial product offering will include a range of functional mushroom tinctures, including species such as cordyceps, lion’s mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics.

If you’ve gotten this far, the first thing you might be asking yourself is “What’s a functional mushroom?”

Edible mushrooms like porcini and shiitake are probably something you know about, as are psychedelic mushrooms that might provide hallucinations — functional mushrooms are a bit different.

“They’re a wonderful, natural health supplement,” Silo Wellness CEO Douglas K. Gordon told me from Jamaica. “They have properties that help with different functions— everything from immunity to digestion to focus.”

Functional mushrooms were a $46 billion industry in 2020, and that number is growing annually. While you’re not going to get “high” taking any of the supplements, you will potentially be able to get some health benefits from taking them. Think of it sort of like a multi-vitamin, in that it’s something you would take every day, but over time you’ll start to potentially see positive improvements to your health from taking them.

MORE FOR YOU

Palm Springs In San Diego? Welcome To The Town And Country Resort

Former Head Of Psychiatry Products At FDA Joins Psychedelic Drug Developer Cybin

The Future Of Psychedelic Medicine Might Skip The Trip

The initial lineup includes five different tinctures, each with a unique health benefit:

One Mind: A coffee-flavored blend of lion’s mane and gingko biloba designed to improve focus and cognitive function.
One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function.
One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion.
One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health.
One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.

In the short-term the brand is taking to market the functional mushrooms, but the hope if that in doing so its also able to start more of a narrative about mushrooms in general, hopefully helping to pave the way in the long term for psychedelics.

“The bigger goal is to destigmatize [mushrooms] and to get people to look at it without all the concerns that have because of all these preconceived notions,” Gordon says.

The idea is that by making the public more aware of mushrooms and their health benefits, they can pave a smoother path for psychedelics potentially being legally available more widely as well.

“On a global level, people who now have a brand name that they trust they can have an affinity towards, or even just a curiosity to learn more, can now learn about mushrooms, and then in the process it brings down that that sort of concerned fear around psychedelics and now we have this great opportunity to be able to educate them about psychedelics,” Gordon says. “So in the first phase we get them a better health and wellness and in the second phase, we give him this much more substantive transformative opportunity to to tap into the benefits of psychedelics in terms of overall health and wellness.”

Given that the mushrooms are functional, they’re also legal to purchase everywhere. You’ll be able to purchase the Marley One tinctures online as well as through retailers across the country.

“As a family, we seek to use our platform to inspire positive change, and the launch of the Marley One mushroom brand, in collaboration with a pioneering company like Silo Wellness, allows us to do just that by marrying ancient wisdom with modern science,” Cedella Marley, CEO of Bob Marley Group of Companies said in a prepared statement. “It’s our wish that these products will empower people to experience oneness with nature and the universe at large – and ultimately, achieve greater self-actualization.”

Bob Marley’s family launches functional and psychedelic mushroom brand with Silo Wellness

Marley One Launches The First Global Functional And Psychedelic Mushroom Brand

Don’t worry about a thing – Bob Marley’s family is partnering with Silo Wellness (SILO) to launch the first global consumer brand of functional and psychedelic mushrooms, Marley One. The first round of products will be a line of functional mushroom tinctures for a variety of benefits such as immunity, sleep, cognitive function, and gut support. The psychedelic mushroom products will be introduced later this year, followed by functional mushroom gummies, capsules, and cosmetics. Cedella Marley hopes that “these products will empower people to experience oneness with nature and the universe at large – and ultimately, achieve greater self-actualization.”

PDF of article

Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

VANCOUVER (June 24, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

The sustainable, reproducible and easily scalable process will be used to rapidly generate therapeutic products from psychoactive fungi species that contain psilocybin, other psychoactive compounds and a range of additional beneficial compounds, some of which Numinus researchers characterized for the first time in psychedelic fungi. The resulting psychedelic products are intended to be delivered in micro or macro dosages to help treat mental health disorders that affect millions of people around the world.

“At Numinus, one of the key goals of our lab’s research and discovery work is to support accessibility to psychedelic-assisted psychotherapies,” said Sharan Sidhu, Numinus Bioscience General Manager and Science Officer. “The rapid production process announced today meets that goal by enhancing our ability to seamlessly formulate safe and effective products with consistent psychoactive properties at scale, with the regulatory confidence that comes with standardized products.”

Numinus initially tested the production process to rapidly generate a Psilocybe species extract as ‘proof of concept’. Results revealed a highly efficient, scalable process that can be applied to other species of psychoactive fungi. Numinus will assess the clinical efficacy and safety of an extract generated using its proprietary technology in an upcoming Phase 1 clinical trial, which was announced in April 2021. The Company’s goal is to scale up the proprietary technology to make psychedelic products generated from psychoactive fungi more readily available in a market that may become regulated in the future.

“As research interest and demand for compassionate access to psychedelics grows, patients will require safe therapeutic products that offer consistent psychoactive properties and are scalable,” said Payton Nyquvest, CEO, Numinus. “With that in mind, we believe that the rapid production process has the potential to transform the sector and ensure that as many people as possible have the opportunity to benefit from mental health treatments and support their wellbeing.”

Today’s announcement reinforces the leadership of the Numinus Bioscience lab in novel psychedelic therapeutics development, and highlights the opportunities resulting from the intellectual property strategy that Numinus is pursuing. This includes basic research into laboratory discoveries and processes that are reproducible, sustainable, cost-efficient and patentable.

Under Canada’s Controlled Drugs and Substances Act, Numinus Bioscience can possess, produce, assemble, sell, export, and deliver a wide variety of psychedelics including Ketamine, Lysergic acid diethylamide (LSD), Mescaline, N,N-Dimethyltryptamine (DMT), N-Methyl-3,4, methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin.

###

About Numinus

Numinus Wellness (TSX-V: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

Forward-Looking Statements

For further information:

May Lee

Communications Manager

Numinus

For media inquiries:

Catherine Snider

Kaiser & Partners

Numinus Announces Grant of Stock Options

VANCOUVER, BC, June 24, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announces that it has granted 1,825,000 incentive stock options (the “Options”) to directors, officers and employees of the Company, which are subject to regulatory approval.

Of the 1,825,000 Options granted during the month of May, 810,000 were issued to directors and an officer of Numinus, which have an exercise price of $0.90 per common share and are exercisable until May 19, 2023. The 1,015,000 Options issued to employees have exercise prices ranging between $0.87 and $1.00 with expiry dates ranging from May 1, 2023 to May 17, 2023.

The Company’s Stock Option Plan allows for the issuance of up to 10% of issued and outstanding share capital in the form of incentive stock options. As the result of the above grants, the Company has 8,931,500 options issued, representing approximately 4.42% of the issued and outstanding share capital.

About Numinus

Numinus Wellness (TSX-V: NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

Forward-Looking Statements

For further information:

May Lee

Communications Manager

Numinus

For media inquiries:

Catherine Snider

Kaiser & Partners

June 23, 2021March 10, 2022

Mydecine Innovations Group (MYCOF) Stock Sees Double-Digit Rally: What Next?

In recent times, the psychedelics based wellness space has garnered a lot of attention among investors and one of the companies that could be worth tracking at this point is that of Mydecine Innovations Group Inc (OTCMKTS:MYCOF).

Yesterday, the Mydecine stock was in the news after Roth Capital Partners started covering the stock and gave it a buy rating. The stock jumped by as much as 20% after investors piled on to its following the bullish call from the analysts at Roth Capital. In addition to that buy rating, the firm set the target price of the stock at $3 a share.

Roth Capital suggested that the smoking cessation therapies that from Mydecine have ‘blockbuster potential’ and that was one of the major factors behind the rating. In addition to that, in the note the firm stated that Mydecine is the first company which is trying to deploy unadulterated psilocybin from fungal mushrooms for not only the treatment of post traumatic stress disorder but also smoking cessation.

The note stated that the company is looking to complete the advanced clinical trials with regards to both these products over the course of the next 18 to 24 months. It might be a good time for investors to start tracking the stock.

Market Reaction:

On Tuesday, MYCOF stock jumped by 19.70% to $0.2844 with more than 1.40 million shares, compared to its average volume of 691K shares. The stock has moved within a range of $ 0.2253 – 0.2884 after opening the trade at $0.2468. Over the past 52-week, the stock has been trading within a range of $0.1990 – 0.5200.

‍

June 23, 2021March 10, 2022

OPTIMI HEALTH ENGAGES U.S. BASED LAW FIRM FOR PATENT SUPPORT

VANCOUVER, BC (GLOBE NEWSWIRE – June 23, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products today announced that Thomas Finetti, partner at Charney IP Law, has been engaged to oversee ongoing patent activities.

Based in New Jersey, Charney IP Law concentrates its practice on intellectual property law. The firm’s primary focus is on identifying, protecting, licensing, and enforcing intellectual property rights. They provide strategic advice and representation throughout the product life cycle, from research and development of products and services to financing, licensing, and, if necessary, regulatory approval and the enforcement of the rights obtained.

Thomas Finetti brings over 16 years of experience in patent law, combining his strong technical background with his extensive experience in developing effective legal strategies. Thomas has enjoyed consistent success in growing and leveraging the intellectual property assets of companies of all sizes, including early-stage companies. Over the course of his career, Thomas has prepared and prosecuted patents in the pharmaceutical, chemical, biotechnology, gene therapy, and diagnostic spaces and ensured his client’s patent portfolios were aligned with their long-term objectives. He has conducted substantive due diligence activities in connection with the licensing or purchasing of intellectual property assets, including conducting freedom-to-operate and patent validity analyses.

“I’m delighted to have the opportunity to assist the team at Optimi Health,” notes Mr. Finetti. “I look forward to helping grow their patent estate and to support their vision of transforming the treatment of mental health conditions and the broader health and wellness of its customers.”

Building on the previously announced hiring of Justin Kirkland as Chief Science Officer, Mr. Kirkland will be pursuing IP and patentable all-natural psilocybin formulations and will work closely with Mr. Finetti to beneficially secure these developments for all stakeholders of Optimi. “I am super excited to continue to work with Thomas,” shares Mr. Kirkland. “I’ve experienced great success with him in the past, taking a concept all the way through two issued patents and a successful exit with the sale of those patents for $10M CAD. We’ve begun the process with Thomas to file IP protection across a variety of innovative areas to ensure we provide the most effective products for patient and consumer health. We are highly confident that Thomas’s expertise will ensure the best positioning of Optimi’s technology goals.”

Timing of this engagement is strategically important as Optimi prepares to submit a formal application to Health Canada for its phase 1 dosing study. Health Canada has indicated they have no concerns over the plan as proposed, and upon pending acceptance and final approval, Optimi remains on-track to begin trials in Q3 of this year. Phase 2 in Optimi’s clinical research plan will include applications for the utilization of the Company’s proprietary formulations.

Optimi Health’s CEO Mike Stier states, “A critical aspect of our business is the development of unique genotypes and ongoing advanced research encompassing formulations as well as procedures and processes to produce a number of unique products from Psilocybe mushrooms. Our goal is to advance these formulations through clinical trials towards commercialization as approved therapeutic aids for the treatment of mental health conditions that affect and impact millions of potential patients around the globe. As such, we understand that as the industry matures, intellectual property rights become increasingly important in an environment where licensing, mergers and acquisitions will undoubtedly play a part in future. Consequently, now is the time to ensure we take concrete steps to protect the interests of the Company, its stakeholders, and shareholders, and are very pleased to welcome Thomas to the Optimi team.”

On Behalf of the Board of Directors, Optimi Health Corp.

Mike Stier
President, Chief Executive Officer and Director

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

June 23, 2021March 10, 2022

Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer

Led first-of-its-kind study of group psilocybin therapy for cancer patients with depression
Co-Investigator on a study to evaluate ketamine as a treatment for opioid use disorder
Will lead Novamind’s clinical research arm focused on psychedelic medicine

TORONTO, ON / ACCESSWIRE / June 23, 2021 / Novamind Inc. (CSE: NM | OTC: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce the appointment of Dr. Paul Thielking as Chief Scientific Officer and Principal Investigator of Novamind.

In his new role, Dr. Thielking will oversee all aspects of the Company’s investigator-led studies, originating within Novamind’s best-in-class research sites, and leveraging its contract research organization (CRO) expertise to pursue additional clinical trial mandates from leading psychedelic drug developers. He will also lead the development of Novamind’s psychedelic therapy protocols for conditions including cancer-related depression and end-of-life anxiety, available as treatments for clients and educational programs for clinicians.

Dr. Thielking is board certified in psychiatry and hospice & palliative medicine and has an outstanding track record in innovative clinical program development and research initiatives. Dr. Thielking led the Huntsman Cancer Institute’s (“HCI”) psycho-oncology service at the University of Utah, where he also taught medical students, psychiatry residents and palliative care physicians. At HCI, he successfully integrated ketamine-assisted psychotherapy services within an outpatient oncology clinic. In his previous role as Associate Professor in the Department of Psychiatry at the University of Utah, Dr. Thielking developed the foundation for a new psychedelic-assisted therapy and research program. In 2020, Dr. Thielking completed the California Institute of Integral Studies’ Certification of Psychedelic Therapy and Research.

“There is an urgent need to find better solutions for the millions of people who are suffering from mental health disorders. Advancing clinical research for psychedelic medicine to address treatment-resistant mental illnesses and supporting patients by developing novel approaches to care for underserved conditions like cancer-related depression, is the next step in my life’s work,” said Dr. Thielking. “Novamind’s growing network of clinics and clinical research sites will accelerate efforts to reach more people with more effective treatment options. I am thrilled to join Novamind’s senior leadership team.”

Dr. Thielking is uniquely positioned to lead Novamind in the role of Chief Scientific Officer. He is currently leading exciting new research initiatives, including a first-of-its-kind pilot study to administer psilocybin in a group setting for cancer patients with depression. Cancer patients have significantly higher rates of depression than the general population, and depression is associated with reduced quality of life, increased physical distress, increased desire for hastened death, and higher suicide rates. He is also the Co-Investigator on a study to evaluate the potential role of ketamine in opioid use disorder. In what’s been referred to as a “silent epidemic,” 70 percent of worldwide deaths attributed to drug use are related to opioids, according to the World Health Organization¹.

Yaron Conforti, Novamind CEO and Director said: “Dr. Thielking brings world-class leadership to Novamind’s contract research organization. His expertise in clinical research and his track record for developing innovative treatments in psychiatry and hospice and palliative care will greatly enhance Novamind’s capabilities to scale access to psychedelic medicine.”

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

¹ https://www.who.int/news-room/fact-sheets/detail/opioid-overdose

June 18, 2021March 10, 2022

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

VANCOUVER, BC, June 18, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received approval to graduate to Tier 1 Issuer status on the TSX Venture Exchange (the “TSXV”), effective June 18, 2021.

By qualifying for up-listing to the TSXV’s top tier under the Life Sciences industry segment, Numinus will benefit from improved service standards, reduced compliance obligations and increased access to institutional investors.

“This up-listing is another indication that Numinus has effectively advanced its healthcare strategy, met its business objectives and built a rapidly scalable growth platform to lead the emerging sector of psychedelic-assisted psychotherapy,” said Payton Nyquvest, President, CEO and Chair, Numinus. “Going forward, we expect to achieve near-term catalysts across our business including clinic acquisitions, new intellectual property, MDMA and psilocybin compassionate access trials, in-clinic ketamine-assisted therapy and further up-listings in the US and Canada. All of this is aimed at creating shareholder value, and supporting our ambition to help as many people as possible heal and be well.”

The TSXV classifies listed issuers into different tiers based on standards including historical financial performance, stage of development and financial resources. Tier 1 is the TSXV’s premier tier and is reserved for the TSXV’s most advanced issuers with the most significant financial resources.

###

About Numinus

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals, licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization of psychedelic therapies, due to inconsistent public opinion, perception of the medical-use of psychedelics, delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers; the development and implementation of medical protocols and treatment standard operating procedures for the use of psychedelic therapies; the Company’s goals to develop and implement partnerships with research organizations and other key players in the integrative mental health industry; the Company’s ability to successfully withstand the economic impact of COVID-19; the medical benefits, safety, efficacy, dosing and social acceptance of psychedelics; the approval and/or success of compassionate access clinical trials; the cultivation and harvest of Psilocybe mushrooms; and the availability of trained personnel and medical professionals. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For further information:

May Lee

Communications Manager

Numinus

For media inquiries:

Catherine Snider

Kaiser & Partners